Making a meaningful difference

Turning scientific innovation into meaningful impact

Zymeworks is a royalty-driven organization differentiated by in-house R&D capabilities developing novel medicines for patients with difficult-to-treat diseases. Through our proprietary platforms, deep scientific expertise, and global partnerships, we build and manage a portfolio of healthcare assets designed to deliver long-term impact across multiple therapeutic indications.

Partner with us

Integrating partnerships and collaborations is core to our business strategy and allows us to accelerate our efforts to bring novel therapeutics to the broadest group of patients.

News

April 27, 2026

Jazz Pharmaceuticals Announces FDA Acceptance and Priority Review of Supplemental Biologics License Application for Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2+ Locally Advanced or Metastatic GEA

April 21, 2026

Zymeworks Presents New Phase 1 Data for ZW191, a Folate Receptor Alpha-Targeting ADC at AACR Annual Meeting 2026

April 17, 2026

Zymeworks Presents New Preclinical Data at AACR 2026 Highlighting Broad Antibody-Drug Conjugate Programs Including Novel RAS-Targeting Platform